Meeting
2023 ASCO Annual Meeting
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
Authors
Shao Zhimin
Fudan University Shanghai Cancer Center, Shanghai, China
Shao Zhimin , Lei Fan , Ma Linxiaoxi , Songyang Wu , Li Chen , Xiyu Liu , Wenjuan Zhang , Xin Hu , Yizhou Jiang , Zhonghua Wang , Huajun Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT04395989
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3011)
DOI
10.1200/JCO.2023.41.16_suppl.3011
Abstract #
3011
Poster Bd #
209
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).
First Author: Philippa Corrie
Poster
2014 ASCO Annual Meeting
tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
First Author: Denise A. Yardley
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Ru Jia
